Mercado Global de Hiperlipidemia – Tendências do Setor e Previsão para 2029

Análise e dimensão do mercado

Nos últimos anos, prevê-se que o mercado da hiperlipidemia cresça rapidamente durante o período de previsão. A hiperlipidemia é uma condição altamente prevalente, especialmente nos países ricos. Também está a aumentar globalmente. 94 milhões de pessoas com mais de 20 anos nos Estados Unidos têm níveis elevados de colesterol total. Isto equivale a cerca de metade de todos os adultos nos Estados Unidos. As pessoas com hiperlipidemia não tratada têm duas vezes mais probabilidade do que aquelas com níveis normais de colesterol de desenvolver doença arterial coronária (DAC). Isto pode causar a obstrução das artérias, o que pode causar ataques cardíacos, acidentes vasculares cerebrais e outras complicações perigosas. Por outro lado, a hiperlipidemia é habitualmente muito tratável e estas situações de emergência podem ser evitadas.

A Data Bridge Market Research analisa que o mercado da hiperlipidemia foi avaliado em 18,97 mil milhões de dólares em 2021 e deverá atingir os 23,84 mil milhões de dólares até 2029, registando um CAGR de 2,90% durante o período de previsão de 2022 a 2029. O relatório de mercado com curadoria da Data A equipa da Bridge Market Research inclui análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Definição de mercado

A hiperlipidemia é uma condição médica descrita pelos elevados níveis de gordura na corrente sanguínea. Acidente vascular cerebral, doença vascular periférica , obesidade, aterosclerose , hipertensão, diabetes e distúrbios cardiovasculares podem ser causados ​​por níveis anormalmente elevados de lípidos e/ou lipoproteínas. Fatores genéticos, estilos de vida inadequados e uma dieta inadequada são as causas mais comuns. As estatinas, os inibidores da Proproteína Convertase Subtilisina/Kexin tipo 9 (PCSK9), os sequestradores de ácidos biliares, os derivados ou fibratos do ácido fíbrico e as combinações e outros medicamentos anti-hiperlipidémicos são alguns dos tratamentos de hiperlipidemia mais utilizados regularmente. Esta condição é também denominada colesterol elevado. 

Âmbito do relatório e segmentação de mercado

Dinâmica do mercado da hiperlipidemia

Motoristas

• Aumento da prevalência de hiperlipidemia

Estima-se que a crescente prevalência da hiperlipidemia a nível mundial aumente o crescimento do mercado. Juntamente com isto, a crescente consciencialização da população sobre o risco de doenças cardiovasculares devido à hipercolesterolemia persistente impulsionará a taxa de crescimento do mercado da hiperlipidemia. Segundo a Organização Mundial de Saúde (OMS), as doenças cardiovasculares (DCV) ceifaram a vida a 17,9 milhões de pessoas em todo o mundo em 2019, sendo responsáveis ​​por 32% de todas as mortes.

• Aumentar o investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado da hiperlipidemia é o aumento dos gastos em saúde que ajuda a melhorar as suas infraestruturas. Além disso, várias organizações governamentais pretendem melhorar a infra-estrutura de saúde aumentando o financiamento e isto influenciará ainda mais a dinâmica do mercado.

• Número crescente da população geriátrica

Estima-se que o aumento da população geriátrica aumente a expansão do mercado durante o período de previsão de 2022-2029. De acordo com a Organização Mundial de Saúde (OMS), a população geriátrica mundial, estimada em mais de 524 milhões em 2010, deverá aumentar para quase 2 mil milhões até 2050. Devido ao seu sistema imunitário comprometido, os geriátricos são mais suscetíveis ao colesterol .

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hyperlipidemia market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of hyperlipidemia market. Surging use of statin therapy and rising incidences of obesity are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hyperlipidemia market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of hyperlipidemia during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hyperlipidemia market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This hyperlipidemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hyperlipidemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hyperlipidemia is a chronic, progressive condition that necessitates dietary and lifestyle adjustments and the use of additional lipid-lowering drugs. Patients with premature coronary artery disease (CAD), defined as CAD that develops in males before the age of 55 to 60 and females before the age of 65, had the greatest level of hyperlipidemia. Hyperlipidemia is around 75-85 percent in the above-mentioned circumstances, compared to 40 to 48 percent in a control population of the same age, but without early coronary artery disease.

Hyperlipidemia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hyperlipidemia Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the hyperlipidemia market.

Recent Development

• In December 2021, Novartis announced the U.S. Food and Drug Administration (FDA) approval of Leqvio (inclisiran). It is the first and only small interfering RNA (siRNA) therapy that lowers low-density lipoprotein cholesterol with two doses annually, after an initial dose and one at three months. Leqvio lowers LDL-C levels in the bloodstream by enhancing the liver's natural ability to suppress the creation of a protein that contributes to excessive cholesterol levels in the bloodstream.

Global Hyperlipidemia Market Scope

The hyperlipidemia market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Familial
• Acquired

Treatment

• Statins
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• Combination
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hyperlipidemia Market Regional Analysis/Insights

The hyperlipidemia market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hyperlipidemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hyperlipidemia market because of the rising prevalence of hyperlipidemia and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing number of geriatric population in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hyperlipidemia Market Share Analysis

The hyperlipidemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hyperlipidemia market.

Some of the major players operating in the hyperlipidemia market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Bristol-Myers Squibb Company (U.S.)
• Eli Lilly and Company (U.S.)
• Regeneron Pharmaceuticals Inc. (U.S.)
• Amgen Inc. (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Alnylam Pharmaceuticals, Inc. (U.S.)
• (Índia)
• Esperion Therapeutics, Inc.
• Formac Pharmaceuticals NV (Bélgica)

SKU-54515